Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13430%2F22%3A43897486" target="_blank" >RIV/44555601:13430/22:43897486 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10448082

Výsledek na webu

<a href="https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152" target="_blank" >https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/dia.2022.0152" target="_blank" >10.1089/dia.2022.0152</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Popis výsledku v původním jazyce

Background: The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint.Methods: The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months.Results: One hundred ninety-one adults with T1D (mean age 40 +/- 13 years, HbA1c 8.1% +/- 3.4% [65 +/- 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% +/- 3.1% [54.1 +/- 10.1 mmol/mol] vs. 7.7% +/- 3.3% [61.2 +/- 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia (&lt;70 mg/dL [&lt;3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% +/- 2.8% vs. 6.4% +/- 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) (0.9% +/- 1.0% vs. 2.3% +/- 2.5%, P &lt; 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% +/- 14.8% vs. 57.8% +/- 17.0%), P = 0.0002.Conclusions: rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).

Název v anglickém jazyce

Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Popis výsledku anglicky

Background: The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint.Methods: The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months.Results: One hundred ninety-one adults with T1D (mean age 40 +/- 13 years, HbA1c 8.1% +/- 3.4% [65 +/- 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% +/- 3.1% [54.1 +/- 10.1 mmol/mol] vs. 7.7% +/- 3.3% [61.2 +/- 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia (&lt;70 mg/dL [&lt;3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% +/- 2.8% vs. 6.4% +/- 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) (0.9% +/- 1.0% vs. 2.3% +/- 2.5%, P &lt; 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% +/- 14.8% vs. 57.8% +/- 17.0%), P = 0.0002.Conclusions: rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

DIABETES TECHNOLOGY &amp; THERAPEUTICS

ISSN

1520-9156

e-ISSN

1557-8593

Svazek periodika

24

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

859-867

Kód UT WoS článku

000892073400001

EID výsledku v databázi Scopus

—